{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11","upperLimit":"40","value":"22"},{"groupId":"OG001","lowerLimit":"35","upperLimit":"93","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"The presence or absence of tumor cells at the end of induction assessed by studying tissue and/or blood/marrow. Details of methods and criteria used can be found in Shiramizu at al. BJH 153:758-763, 2011 (full citation in the citation section).","dispersionType":"95% Confidence Interval","groups":[{"description":"Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.","id":"OG000","title":"Group B (Chemotherapy, Protective Therapy, Monoclonal Antib.)"},{"description":"Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.","id":"OG001","title":"Group C (Chemotherapy, Monoclonal Antibody Therapy)"}],"paramType":"NUMBER","populationDescription":"Population analyzed included patients submitting samples for minimal disease assay at end induction","reportingStatus":"POSTED","timeFrame":"Not Provided","title":"Minimal Residual Disease","type":"PRIMARY","unitOfMeasure":"percentage of samples analyzed"}